HDFC Life Insurance trimmed its stake in IPCA Laboratories from 1.39% to 1.07%, selling 7,97,831 shares.
A pharmaceutical manufacturer and marketer, Ipca Labs produces a wide range of medicines across therapeutic areas including antimalarials, anti-infectives, gastrointestinal treatments, and gynecological formulations. The company operates manufacturing facilities across India and exports its products to international markets. Its distinctive strength lies in its expertise in complex drug formulations, established distribution networks across Indian states, and a focus on affordable healthcare solutions for domestic and global markets.
HDFC Life Insurance Company Limited, institutional investor in Indian equities
